
Apple is battling subpoenas in a U.S. Court in California against Qualcomm over allegations that Qualcomm misrepresented certain business practices which artificially boosted shares between 2012 and 2017, reported Reuters.
Attorneys representing both Apple and Qualcomm are making their case as the the lawsuit enters its fourth month. Richard Doren of Gibson, Dunn & Crutcher represents Apple, while Robert Van Nest of Keker, Van Nest & Peters and Anthony Ryan of Cravath, Swaine & Moore act as counsel for Qualcomm.
Related: Qualcomm Wins Appeals $1B EU Antitrust Fine Over Apple Payments
The lawsuit focuses on alleged anticompetitive sales and licensing practices which Qualcomm has denied. Plaintiffs are represented by Jonathan Uslaner of Bernstein Litowitz Berger & Grossman and Gregg Levin of Motley Rice. Steven Strauss of Cooley also represents Qualcomm.
The dispute takes a unique turn as Qualcomm has sought to inquire about communication between Apple and the Federal Trade Commission and Apple’s cooperation with the agency related to an antitrust case the FTC brought in 2017 against Qualcomm. Apple firmly opposes the subpoena, stating that its “communications with the FTC are not relevant to the securities litigation between Qualcomm and its shareholders regarding alleged false statements by Qualcomm.”
Despite the push-back from Apple and representing attorneys for both sides, a judge ruled in March that the case could move forward as a class action. It remains to be seen if the case will be resolved justly.
Featured News
Fortnite Returns to Apple’s U.S. App Store After Five-Year Ban
May 21, 2025 by
CPI
Federal Court to Hear Case on Trump’s Firing of FTC Democrats
May 20, 2025 by
CPI
UK Government Suffers Third Successive Defeat on Data (Use and Access) Bill
May 20, 2025 by
CPI
Sex Toy Retailer Says Google Breaches EU Digital Market Rules
May 20, 2025 by
CPI
Latham & Watkins Expands Brussels Antitrust Team
May 20, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas